Few cases in recent years have generated as much excitement in India and across the world as Novartis’ bid for patenting its cancer drug Glivec in India. India’s Supreme Court delivered its verdict on April 1, 2013, on the case bringing to closure a 7 year-old legal battle. Novartis lost. But challenges and  questions remain.

Here are web links to my reports/podcasts on the subject


1. http://www.lancet.com/journals/lancet/article/PIIS0140-6736(13)60826-0/fulltext  (The Lancet, The World Report)

2. http://download.thelancet.com/flatcontentassets/audio/lancet-news/2013/12april.mp3 (The  Lancet, podcast)

3. http://www.dnaindia.com/analysis/1820025/column-india-pariah-or-pathbreaker-of-pharma-world (Column,  Edgy Nation, DNA)

4. http://www.ip-watch.org/2013/04/01/novartis-loses-patent-bid-lessons-from-indias-3d-experience/ (Report, Intellectual Property Watch)


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s